YA reports consultancy fees from Bristol Myers Squibb (Celgene Corp), CRISPR/Vertex and Silence Therapeutics; research funding from Agios, Bristol Myers Squibb (Celgene Corp), Cerus, Sobi Inc. and Novartis; membership on an advisory committee for Cerus, Bristol Myers Squibb (Celgene Corp), Agios and Chiesi. AK reports receiving consulting fees/honoraria from Agios Pharmaceuticals, Bristol Myers Squibb (Celgene Corp), Chiesi Farmaceutici, CRISPR Therapeutics/Vertex, CSL Vifor, Novartis and Novo Nordisk; and research support from Bristol Myers Squibb (Celgene Corp) and Novartis. ATT reports consultancy fees from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos and Roche; and research funding from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos and Roche. The remaining authors have no competing interests to disclose. All competing interests are outside the present work.